

## Special Issue

# Plant Based Vaccines—A Powerhouse for Global Health 2.0

### Message from the Guest Editors

Plants are emerging as powerful platforms for the production of biopharmaceuticals and industrial proteins. Plant-based vaccines, monoclonal antibodies and other therapeutic proteins show promise as inexpensive yet efficacious approaches to address global health. Vaccines made from plants are safe, easy to generate en masse and can be stored at ambient temperatures. These distinct properties make plant-based vaccines attractive alternatives for providing medicines which have previously been inaccessible and unaffordable to the poor in developing countries. In addition to this, plant-based vaccines can be stockpiled to guard against global pandemics such as Influenza and could be employed in personalized medicine, such as addressing chronic diseases including cancer. Plant-based vaccines can therefore facilitate improvements in global health through multiple conduits. The following Special Issue explores various approaches used to generate plant-based vaccines, with examples provided in the context of global health.

---

### Guest Editors

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Dr. Srividhya Venkataraman

Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada

---

### Deadline for manuscript submissions

closed (31 August 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/81361](https://mdpi.com/si/81361)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).